



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION OF : HU, et al.  
 SERIAL NO. : 08/469,641  
 FILED : June 6, 1995  
 FOR : Human Vascular Endothelial Growth Factor 3  
 EXAMINER : Olsen  
 GROUP ART UNIT : 1812  
 ATTORNEY DOCKET NO. : 325800-463 (PF207)

Assistant Commissioner for Patents  
 Washington, DC 20231

RECEIVED  
 OCT 15 1997

Dear Sir:

Pursuant to 37 C.F.R. §1.56(a), Applicant hereby cites the following documents  
 (copies enclosed) listed on the attached copy of Form PTO-1449 which are believed to be material  
 to the patentability of the above-identified application.

This Information Disclosure Statement is filed in accordance with the paragraph  
 of 37 CFR 1.97 checked below:

       1.97(b) This Information Disclosure Statement is filed:

- (1) Within three months of the filing date of a national application; OR
- (2) Within three months of the date of entry of the national stage of an international application; OR
- (3) Before the mailing of a first Office Action on the merits.

No fee or certification is required.

X 1.97(c)

This Information Disclosure Statement is filed after the period specified in paragraph (b) above, but before the mailing date of either:

- (1) A Final Action under 37 CFR 1.113; OR

10/06/1997 DASH1 0000004 BM:030678 08469641  
 01 FC:186 110.00 CH 130.00 BP


S SP  
 1812  
 #14  
 DE  
 10/20/97

- (2) A Notice of Allowance under 37 CFR 1.311;  
AND is accompanied by either: (check one)  
 the Certification under 37 CFR 1.97(e) as set out below; OR  
 the fee of \$130.00 under 37 CFR 1.17(p).
- 1.97(d) This Information Disclosure Statement is filed after the mailing date of either:  
(1) a Final action under 37 CFR 1.113; OR  
(2) A Notice of Allowance under 37 CFR 1.311;
- BUT before payment of the Issue Fee; AND is accompanied by:  
(1) the Certification under 37 CFR 1.97(e) as set out below; AND  
(2) Petition is hereby made under 37 CFR 1.97(d) for consideration of this Information Disclosure Statement; AND,  
(3) A check in the amount of \$ \_\_\_\_\_ the petition fee set out in 37 CFR 1.17(i).

If this Information Disclosure Statement is being filed under 37 CFR 1.97(c) or 1.97(d), the undersigned Attorney hereby certifies that:

- each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Statement;
- or
- no item or information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to the knowledge of the undersigned Attorney after making reasonable enquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing date of this Statement.

The Commissioner is authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

<b><u>FIRST CLASS CERTIFICATE</u></b>	
I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:	
Assistant Commissioner for Patents Washington, D.C. 20231	
	
J.G. Mullins, Esq.	
Date	9/23/97

Respectfully submitted,



J.G. Mullins, Esq.  
Reg. No. 33,073  
CARELLA, BYRNE, BAIN,  
GILFILLAN, CECCHI, STEWART &  
OLSTEIN  
6 Becker Farm Road  
Roseland, NJ 07068  
Tel. No.: (201) 994-1700  
Fax No. : (201) 994-1744  
Attorney for Applicant(s)